#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain

Johnson & Johnson at #ASCO2026 (Karen Weintraub for Endpoints News) June 1, 2026 06:19 AM EDT R&D J&J's Er­lea­da study suc­ceeds in ear­ly-stage prostate can­cer, but ques­tions re­main Lei Lei Wu News Reporter CHICA­GO — As part of a hor­mone ther­a­py reg­i­men for prostate can­cer, J&J’s Er­lea­da cut the risk of metas­ta­sis or death by 20% when giv­en … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER